| Year |
Citation |
Score |
| 2020 |
Bouabdallaoui N, Tardif JC, Waters DD, Pinto FJ, Maggioni AP, Diaz R, Berry C, Koenig W, Lopez-Sendon J, Gamra H, Kiwan GS, Blondeau L, Orfanos A, Ibrahim R, Grégoire JC, et al. Time-to-treatment initiation of colchicine and cardiovascular outcomes after myocardial infarction in the Colchicine Cardiovascular Outcomes Trial (COLCOT). European Heart Journal. PMID 32860034 DOI: 10.1093/Eurheartj/Ehaa659 |
0.349 |
|
| 2020 |
Diaz R, Li QH, Bhatt DL, Bittner VA, Baccara-Dinet MT, Goodman SG, Jukema JW, Kimura T, Parkhomenko A, Pordy R, Reiner Ž, Roe MT, Szarek M, Tse HF, White HD, et al. Intensity of statin treatment after acute coronary syndrome, residual risk, and its modification by alirocumab: insights from the ODYSSEY OUTCOMES trial. European Journal of Preventive Cardiology. 2047487320941987. PMID 32718237 DOI: 10.1177/2047487320941987 |
0.402 |
|
| 2020 |
Hystad P, Larkin A, Rangarajan S, AlHabib KF, Avezum Á, Calik KBT, Chifamba J, Dans A, Diaz R, du Plessis JL, Gupta R, Iqbal R, Khatib R, Kelishadi R, Lanas F, et al. Associations of outdoor fine particulate air pollution and cardiovascular disease in 157 436 individuals from 21 high-income, middle-income, and low-income countries (PURE): a prospective cohort study. The Lancet. Planetary Health. 4: e235-e245. PMID 32559440 DOI: 10.1016/S2542-5196(20)30103-0 |
0.312 |
|
| 2020 |
Shyamkumar K, Hirsh J, Bhagirath VC, Sinha S, Xu K, Ginsberg JS, Díaz R, Eikelboom JW, Chan NC. Mortality benefit in the COMPASS trial: is it related to superior statistical power or better efficacy and safety? Future Cardiology. PMID 32559114 DOI: 10.2217/Fca-2020-0013 |
0.31 |
|
| 2020 |
White HD, Stewart RAH, Dalby AJ, Stebbins A, Cannon CP, Budaj A, Linhart A, Pais P, Diaz R, Steg PG, Krug-Gourley S, Granger CB, Hochman JS, Koenig W, Harrington RA, et al. In patients with stable coronary heart disease, low-density lipoprotein-cholesterol levels < 70 mg/dL and glycosylated hemoglobin A1c < 7% are associated with lower major cardiovascular events. American Heart Journal. 225: 97-107. PMID 32480059 DOI: 10.1016/J.Ahj.2020.04.004 |
0.4 |
|
| 2020 |
Walli-Attaei M, Joseph P, Rosengren A, Chow CK, Rangarajan S, Lear SA, AlHabib KF, Davletov K, Dans A, Lanas F, Yeates K, Poirier P, Teo KK, Bahonar A, Camilo F, ... ... Diaz R, et al. Variations between women and men in risk factors, treatments, cardiovascular disease incidence, and death in 27 high-income, middle-income, and low-income countries (PURE): a prospective cohort study. Lancet (London, England). PMID 32445693 DOI: 10.1016/S0140-6736(20)30543-2 |
0.343 |
|
| 2020 |
de Souza RJ, Dehghan M, Mente A, Bangdiwala SI, Ahmed SH, Alhabib KF, Altuntas Y, Basiak-Rasała A, Dagenais GR, Diaz R, Amma LI, Kelishadi R, Khatib R, Lear SA, Lopez-Jaramillo P, et al. Association of nut intake with risk factors, cardiovascular disease, and mortality in 16 countries from 5 continents: analysis from the Prospective Urban and Rural Epidemiology (PURE) study. The American Journal of Clinical Nutrition. PMID 32433740 DOI: 10.1093/Ajcn/Nqaa108 |
0.352 |
|
| 2020 |
Bhatt DL, Briggs AH, Reed SD, Annemans L, Szarek M, Bittner VA, Diaz R, Goodman SG, Harrington RA, Higuchi K, Joulain F, Jukema JW, Li QH, Mahaffey KW, Sanchez RJ, et al. Cost-Effectiveness of Alirocumab in Patients With Acute Coronary Syndromes: The ODYSSEY OUTCOMES Trial. Journal of the American College of Cardiology. 75: 2297-2308. PMID 32381160 DOI: 10.1016/J.Jacc.2020.03.029 |
0.355 |
|
| 2020 |
Schwartz GG, Steg PG, Szarek M, Bittner VA, Diaz R, Goodman SG, Kim YU, Jukema JW, Pordy R, Roe MT, White HD, Bhatt DL. Peripheral Artery Disease and Venous Thromboembolic Events After Acute Coronary Syndrome: Role of Lipoprotein(a) and Modification by Alirocumab: Prespecified Analysis of a Randomized Clinical Trial. Circulation. PMID 32223446 DOI: 10.1161/Circulationaha.120.046524 |
0.373 |
|
| 2020 |
Bhatt DL, Eikelboom JW, Connolly SJ, Steg PG, Anand SS, Verma S, Branch KRH, Probstfield J, Bosch J, Shestakovska O, Szarek M, Maggioni AP, Widimský P, Avezum A, Diaz R, et al. The Role of Combination Antiplatelet and Anticoagulation Therapy in Diabetes and Cardiovascular Disease: Insights from the COMPASS Trial. Circulation. PMID 32223318 DOI: 10.1161/Circulationaha.120.046448 |
0.367 |
|
| 2020 |
Bonaca MP, Bauersachs RM, Anand SS, Debus ES, Nehler MR, Patel MR, Fanelli F, Capell WH, Diao L, Jaeger N, Hess CN, Pap AF, Kittelson JM, Gudz I, Mátyás L, ... ... Diaz R, et al. Rivaroxaban in Peripheral Artery Disease after Revascularization. The New England Journal of Medicine. PMID 32222135 DOI: 10.1056/Nejmoa2000052 |
0.332 |
|
| 2020 |
Shin SH, Claggett B, Pfeffer MA, Skali H, Liu J, Aguilar D, Diaz R, Dickstein K, Gerstein HC, Køber LV, Lawson FC, Lewis EF, Maggioni AP, McMurray JJV, Probstfield JL, et al. Hyperglycaemia, ejection fraction and the risk of heart failure or cardiovascular death in patients with type 2 diabetes and a recent acute coronary syndrome. European Journal of Heart Failure. PMID 32212368 DOI: 10.1002/Ejhf.1790 |
0.368 |
|
| 2020 |
Bainey KR, Welsh RC, Connolly SJ, Marsden T, Bosch J, Fox KAA, Steg PG, Vinereanu D, Connolly DL, Berkowitz SD, Foody JM, Probstfield JL, Branch KR, Lewis BS, Diaz R, et al. Rivaroxaban Plus Aspirin Versus Aspirin Alone in Patients with Prior Percutaneous Coronary Intervention (COMPASS-PCI). Circulation. PMID 32178526 DOI: 10.1161/Circulationaha.119.044598 |
0.33 |
|
| 2020 |
Teerlink JR, Diaz R, Felker GM, McMurray JJV, Metra M, Solomon SD, Legg JC, Büchele G, Varin C, Kurtz CE, Malik FI, Honarpour N. Omecamtiv Mecarbil in Chronic Heart Failure With Reduced Ejection Fraction: Rationale and Design of GALACTIC-HF. Jacc. Heart Failure. PMID 32035892 DOI: 10.1016/J.Jchf.2019.12.001 |
0.334 |
|
| 2020 |
Goodman SG, Steg PG, Szarek M, Bhatt DL, Bittner VA, Diaz R, Harrington RA, Jukema JW, White HD, Zeiher AM, Schwartz GG. Sustained Low-Density Lipoprotein Cholesterol Lowering With Alirocumab in ODYSSEY OUTCOMES. Journal of the American College of Cardiology. 75: 448-451. PMID 32000957 DOI: 10.1016/J.Jacc.2019.11.030 |
0.365 |
|
| 2020 |
Dehghan M, Mente A, Rangarajan S, Mohan V, Lear S, Swaminathan S, Wielgosz A, Seron P, Avezum A, Lopez-Jaramillo P, Turbide G, Chifamba J, AlHabib KF, Mohammadifard N, Szuba A, ... ... Diaz R, et al. Association of egg intake with blood lipids, cardiovascular disease, and mortality in 177,000 people in 50 countries. The American Journal of Clinical Nutrition. PMID 31965140 DOI: 10.1093/Ajcn/Nqz348 |
0.314 |
|
| 2020 |
Bittner VA, Szarek M, Aylward PE, Bhatt DL, Diaz R, Edelberg JM, Fras Z, Goodman SG, Halvorsen S, Hanotin C, Harrington RA, Jukema JW, Loizeau V, Moriarty PM, Moryusef A, et al. Effect of Alirocumab on Lipoprotein(a) and Cardiovascular Risk After Acute Coronary Syndrome. Journal of the American College of Cardiology. 75: 133-144. PMID 31948641 DOI: 10.1016/J.Jacc.2019.10.057 |
0.345 |
|
| 2020 |
Gerstein HC, Hart R, Colhoun HM, Diaz R, Lakshmanan M, Botros FT, Probstfield J, Riddle MC, Rydén L, Atisso CM, Dyal L, Hall S, Avezum A, Basile J, Conget I, et al. The effect of dulaglutide on stroke: an exploratory analysis of the REWIND trial. The Lancet. Diabetes & Endocrinology. PMID 31924562 DOI: 10.1016/S2213-8587(19)30423-1 |
0.311 |
|
| 2020 |
Bethel A, Diaz R, Castellana N, Gerstein HC, Lakshmanan M. 944-P: HbA1c Change Is Associated with Retinopathy Outcomes during GLP-1RA CVOT Follow-Up Diabetes. 69. DOI: 10.2337/Db20-944-P |
0.302 |
|
| 2020 |
Wijkman MO, Claggett B, Diaz R, Gerstein HC, Kober L, Lewis E, Maggioni AP, Wolsk E, Aguilar D, Bentley-Lewis R, Mcmurray JJ, Probstfield JL, Riddle MC, Tardif J, Solomon S, et al. 1421-P: The Impact of Blood Pressure on Risk of Death Is Influenced by Prior Cardiovascular Disease in Patients with Type 2 Diabetes and a Recent Coronary Event Diabetes. 69. DOI: 10.2337/Db20-1421-P |
0.37 |
|
| 2020 |
Ferrannini G, Gerstein H, Colhoun H, Dagenais G, Diaz R, Dyal L, Lakshmanan M, Mellbin L, Probstfield J, Riddle M, Shaw J, Ryden L. Dulaglutide is cardioprotective with or without background metformin in patients with diabetes and established or high risk for coronary vascular disease. A subgroup analysis of the REWIND Trial European Heart Journal. 41. DOI: 10.1093/ehjci/ehaa946.3353 |
0.302 |
|
| 2020 |
Landmesser U, McGinniss J, Steg PG, Bhatt D, Bittner V, Diaz R, Goodman S, Harrington RA, Jukema JW, Laucevicius A, Pecin I, Pordy R, Poulsen S, Roe M, Sourdille T, et al. Achievement Of New European Dyslipidemia-Guideline Low-Density Lipoprotein Cholesterol Treatment Goals After Acute Coronary Syndrome: Insights From Odyssey Outcomes Journal of the American College of Cardiology. 75: 1978. DOI: 10.1016/S0735-1097(20)32605-X |
0.353 |
|
| 2020 |
Bittner V, McGinniss J, Schwartz GG, Bhatt D, Chua T, Silva HAd, Diaz R, Dorobantu M, Goodman S, Harrington RA, Jukema JW, Kim Y, Pordy R, Roe M, Szarek M, et al. Alirocumab And Cardiovascular Outcomes In Women After An Acute Coronary Syndrome: An Odyssey Outcomes Trial Analysis Journal of the American College of Cardiology. 75: 1854. DOI: 10.1016/S0735-1097(20)32481-5 |
0.339 |
|
| 2020 |
Teerlink JR, Diaz R, Felker GM, McMurray J, Metra M, Solomon SD, Legg J, Varin C, Kurtz C, Malik F, Abbasi SA. Baseline Characteristics From The Cardiovascular Outcomes Trial Of Omecamtiv Mecarbil, Galactic-Hf (Global Approach To Lowering Adverse Cardiac Outcomes Through Improving Contractility In Heart Failure) Journal of the American College of Cardiology. 75: 754. DOI: 10.1016/S0735-1097(20)31381-4 |
0.317 |
|
| 2020 |
Szarek M, Valgimigli M, Zeiher A, Steg PG, Bhatt D, Bittner V, Chiang C, Diaz R, Goodman S, Gotcheva N, Harrington RA, Jukema JW, Kim H, Kim Y, Morais J, et al. Effect Of Alirocumab On First And Total Revascularizations In Patients With Recent Acute Coronary Syndrome In The Odyssey Outcomes Trial Journal of the American College of Cardiology. 75: 157. DOI: 10.1016/S0735-1097(20)30784-1 |
0.305 |
|
| 2020 |
Hagstrom E, Steg PG, Szarek M, Bhatt D, Bittner V, Danchin N, Diaz R, Goodman S, Harrington RA, Jukema JW, Kim Y, Liberopoulos E, Marx N, McGinniss J, Roe M, et al. Apolipoprotein B, Pcsk9 Inhibition With Alirocumab, And Ischemic Cardiovascular Events After Acute Coronary Syndrome: Insights From The Odyssey Outcomes Trial Journal of the American College of Cardiology. 75: 75. DOI: 10.1016/S0735-1097(20)30702-6 |
0.325 |
|
| 2019 |
Sinnaeve PR, Schwartz GG, Wojdyla DM, Alings M, Bhatt DL, Bittner VA, Chiang CE, Correa Flores RM, Diaz R, Dorobantu M, Goodman SG, Jukema JW, Kim YU, Pordy R, Roe MT, et al. Effect of alirocumab on cardiovascular outcomes after acute coronary syndromes according to age: an ODYSSEY OUTCOMES trial analysis. European Heart Journal. PMID 31732742 DOI: 10.1093/Eurheartj/Ehz809 |
0.37 |
|
| 2019 |
Szarek M, Steg PG, DiCenso D, Bhatt DL, Bittner VA, Budaj A, Diaz R, Goodman SG, Gotcheva N, Jukema JW, Pordy R, Roe MT, Sourdille T, White HD, Xavier D, et al. Alirocumab Reduces Total Hospitalizations and Increases Days Alive and Out of Hospital in the ODYSSEY OUTCOMES Trial. Circulation. Cardiovascular Quality and Outcomes. 12: e005858. PMID 31707826 DOI: 10.1161/Circoutcomes.119.005858 |
0.369 |
|
| 2019 |
Eikelboom JW, Bosch JJ, Connolly SJ, Shestakovska O, Dagenais GR, Hart RG, Leong DP, O'Donnell M, Fox KAA, Bhatt DL, Cairns JA, Tasto C, Berkowitz SD, Cook Bruns N, Muehlhofer E, ... Diaz R, et al. Major Bleeding in Patients With Coronary or Peripheral Artery Disease Treated With Rivaroxaban Plus Aspirin. Journal of the American College of Cardiology. 74: 1519-1528. PMID 31537259 DOI: 10.1016/J.Jacc.2019.07.065 |
0.336 |
|
| 2019 |
Yusuf S, Joseph P, Rangarajan S, Islam S, Mente A, Hystad P, Brauer M, Kutty VR, Gupta R, Wielgosz A, AlHabib KF, Dans A, Lopez-Jaramillo P, Avezum A, Lanas F, ... ... Diaz R, et al. Modifiable risk factors, cardiovascular disease, and mortality in 155 722 individuals from 21 high-income, middle-income, and low-income countries (PURE): a prospective cohort study. Lancet (London, England). PMID 31492503 DOI: 10.1016/S0140-6736(19)32008-2 |
0.359 |
|
| 2019 |
Dagenais GR, Leong DP, Rangarajan S, Lanas F, Lopez-Jaramillo P, Gupta R, Diaz R, Avezum A, Oliveira GBF, Wielgosz A, Parambath SR, Mony P, Alhabib KF, Temizhan A, Ismail N, et al. Variations in common diseases, hospital admissions, and deaths in middle-aged adults in 21 countries from five continents (PURE): a prospective cohort study. Lancet (London, England). PMID 31492501 DOI: 10.1016/S0140-6736(19)32007-0 |
0.306 |
|
| 2019 |
Bhatt DL, Steg PG, Mehta SR, Leiter LA, Simon T, Fox K, Held C, Andersson M, Himmelmann A, Ridderstråle W, Chen J, Song Y, Diaz R, Goto S, James SK, et al. Ticagrelor in patients with diabetes and stable coronary artery disease with a history of previous percutaneous coronary intervention (THEMIS-PCI): a phase 3, placebo-controlled, randomised trial. Lancet (London, England). PMID 31484629 DOI: 10.1016/S0140-6736(19)31887-2 |
0.351 |
|
| 2019 |
Roe MT, Li QH, Bhatt DL, Bittner VA, Diaz R, Goodman SG, Harrington RA, Jukema JW, Lopez-Jaramillo P, Lopes RD, Louie MJ, Moriarty PM, Szarek M, Vogel R, White HD, et al. Risk Categorization Using New American College of Cardiology/American Heart Association Guidelines for Cholesterol Management and Its Relation to Alirocumab Treatment Following Acute Coronary Syndromes. Circulation. PMID 31475572 DOI: 10.1161/Circulationaha.119.042551 |
0.326 |
|
| 2019 |
Goodman SG, Aylward PE, Szarek M, Chumburidze V, Bhatt DL, Bittner VA, Diaz R, Edelberg JM, Hanotin C, Harrington RA, Jukema JW, Kedev S, Letierce A, Moryusef A, Pordy R, et al. Effects of Alirocumab on Cardiovascular Events After Coronary Bypass Surgery. Journal of the American College of Cardiology. 74: 1177-1186. PMID 31466614 DOI: 10.1016/J.Jacc.2019.07.015 |
0.344 |
|
| 2019 |
Gerstein HC, Colhoun HM, Dagenais GR, Diaz R, Lakshmanan M, Pais P, Probstfield J, Riesmeyer JS, Riddle MC, Rydén L, Xavier D, Atisso CM, Dyal L, Hall S, Rao-Melacini P, et al. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet (London, England). PMID 31189511 DOI: 10.1016/S0140-6736(19)31149-3 |
0.348 |
|
| 2019 |
White HD, Steg PG, Szarek M, Bhatt DL, Bittner VA, Diaz R, Edelberg JM, Erglis A, Goodman SG, Hanotin C, Harrington RA, Jukema JW, Lopes RD, Mahaffey KW, Moryusef A, et al. Effects of alirocumab on types of myocardial infarction: insights from the ODYSSEY OUTCOMES trial. European Heart Journal. PMID 31121022 DOI: 10.1093/Eurheartj/Ehz299 |
0.345 |
|
| 2019 |
Steg PG, Szarek M, Bhatt DL, Bittner VA, Brégeault MF, Dalby AJ, Diaz R, Edelberg JM, Goodman SG, Hanotin C, Harrington RA, Jukema JW, Lecorps G, Mahaffey KW, Moryusef A, et al. Effect of Alirocumab on Mortality After Acute Coronary Syndromes: An Analysis of the ODYSSEY OUTCOMES Randomized Clinical Trial. Circulation. PMID 31117810 DOI: 10.1161/Circulationaha.118.038840 |
0.372 |
|
| 2019 |
Moayyedi P, Eikelboom JW, Bosch J, Connolly SJ, Dyal L, Shestakovska O, Leong D, Anand SS, Störk S, Branch KRH, Bhatt DL, Verhamme PB, O'Donnell M, Maggioni AP, Lonn EM, ... ... Diaz R, et al. Pantoprazole to Prevents Gastroduodenal Events in Patients Receiving Rivaroxaban and/or Aspirin in a Randomized, Double-blind, Placebo-controlled Trial. Gastroenterology. PMID 31054846 DOI: 10.1053/J.Gastro.2019.04.041 |
0.332 |
|
| 2019 |
Jukema JW, Szarek M, Zijlstra LE, de Silva HA, Bhatt DL, Bittner VA, Diaz R, Edelberg JM, Goodman SG, Hanotin C, Harrington RA, Karpov Y, Moryusef A, Pordy R, Prieto JC, et al. Patients with Recent Acute Coronary Syndrome and Polyvascular Disease Derive Large Absolute Benefit from Alirocumab: ODYSSEY OUTCOMES Trial. Journal of the American College of Cardiology. PMID 30898609 DOI: 10.1016/J.Jacc.2019.03.013 |
0.399 |
|
| 2019 |
O'Donnell M, Mente A, Rangarajan S, McQueen MJ, O'Leary N, Yin L, Liu X, Swaminathan S, Khatib R, Rosengren A, Ferguson J, Smyth A, Lopez-Jaramillo P, Diaz R, Avezum A, et al. Joint association of urinary sodium and potassium excretion with cardiovascular events and mortality: prospective cohort study. Bmj (Clinical Research Ed.). 364: l772. PMID 30867146 DOI: 10.1136/Bmj.L772 |
0.303 |
|
| 2019 |
Jukema JW, Szarek M, Roe M, Bhatt DL, Bittner V, Silva HAd, Diaz R, Goodman S, Hanotin C, Edelberg J, Harrington R, Karpov Y, Moryusef A, Pordy R, Prieto J, et al. Post-Acute Coronary Syndrome Patients With Polyvascular Disease Derive Large Absolute Benefit From Alirocumab: Odyssey Outcomes Journal of the American College of Cardiology. 73: 2034. DOI: 10.1016/S0735-1097(19)32640-3 |
0.393 |
|
| 2019 |
Goodman SG, Aylward P, Szarek M, Chumburidze V, Bhatt DL, Bittner V, Diaz R, Edelberg J, Hanotin C, Harrington RA, Jukema JW, Kedev S, Moryusef A, Pordy R, López GAR, et al. Patients With Acute Coronary Syndrome, Elevated Atherogenic Lipoproteins, And Prior Coronary Artery Bypass Grafting Derive Large Absolute Benefit From Alirocumab: Insights From The Odyssey Outcomes Trial Journal of the American College of Cardiology. 73: 30. DOI: 10.1016/S0735-1097(19)30639-4 |
0.372 |
|
| 2018 |
Seferovic JP, Bentley-Lewis R, Claggett B, Diaz R, Gerstein HC, Køber LV, Lawson FC, Lewis EF, Maggioni AP, McMurray JJV, Probstfield JL, Riddle MC, Solomon SD, Tardif JC, Pfeffer MA. Retinopathy, Neuropathy, and Subsequent Cardiovascular Events in Patients with Type 2 Diabetes and Acute Coronary Syndrome in the ELIXA: The Importance of Disease Duration. Journal of Diabetes Research. 2018: 1631263. PMID 30648112 DOI: 10.1155/2018/1631263 |
0.356 |
|
| 2018 |
Bonaca MP, Wiviott SD, Morrow DA, Steg PG, Hamm C, Bhatt DL, Storey RF, Cohen M, Kuder J, Im K, Magnani G, Budaj A, Nicolau JC, Parkhomenko A, López-Sendón J, ... ... Diaz R, et al. Reduction in Subtypes and Sizes of Myocardial Infarction With Ticagrelor in PEGASUS-TIMI 54. Journal of the American Heart Association. 7: e009260. PMID 30571502 DOI: 10.1161/Jaha.118.009260 |
0.361 |
|
| 2018 |
Szarek M, White HD, Schwartz GG, Alings M, Bhatt DL, Bittner VA, Chiang CE, Diaz R, Edelberg JM, Goodman SG, Hanotin C, Harrington RA, Jukema JW, Kimura T, Kiss RG, et al. Alirocumab Reduces Total Nonfatal Cardiovascular and Fatal Events in the ODYSSEY OUTCOMES Trial. Journal of the American College of Cardiology. PMID 30428396 DOI: 10.1016/j.jacc.2018.10.039 |
0.385 |
|
| 2018 |
Mente A, O'Donnell M, Rangarajan S, McQueen M, Dagenais G, Wielgosz A, Lear S, Ah STL, Wei L, Diaz R, Avezum A, Lopez-Jaramillo P, Lanas F, Mony P, Szuba A, et al. Urinary sodium excretion, blood pressure, cardiovascular disease, and mortality: a community-level prospective epidemiological cohort study. Lancet (London, England). 392: 496-506. PMID 30129465 DOI: 10.1016/S0140-6736(18)31376-X |
0.348 |
|
| 2018 |
Murphy A, Palafox B, O'Donnell O, Stuckler D, Perel P, AlHabib KF, Avezum A, Bai X, Chifamba J, Chow CK, Corsi DJ, Dagenais GR, Dans AL, Diaz R, Erbakan AN, et al. Inequalities in the use of secondary prevention of cardiovascular disease by socioeconomic status: evidence from the PURE observational study. The Lancet. Global Health. 6: e292-e301. PMID 29433667 DOI: 10.1016/S2214-109X(18)30031-7 |
0.322 |
|
| 2018 |
Gerstein HC, Jung H, Rydén L, Diaz R, Gilbert RE, Yusuf S. Effect of Basal Insulin Glargine on First and Recurrent Episodes of Heart Failure Hospitalization: The ORIGIN Trial (Outcome Reduction With Initial Glargine Intervention). Circulation. 137: 88-90. PMID 29279340 DOI: 10.1161/Circulationaha.117.030924 |
0.301 |
|
| 2018 |
White H, Steg P, Szarek M, Bhatt D, Bittner V, Diaz R, Edelberg J, Goodman S, Hantoin C, Harrington R, Jukema J, Lecorps G, Moryusef A, Pordy R, Roe M, et al. Cardiovascular Outcomes With Alirocumab After Acute Coronary Syndrome: Results of the Odyssey Outcomes Trial Heart Lung and Circulation. 27. DOI: 10.1016/J.Hlc.2018.06.585 |
0.344 |
|
| 2017 |
Joseph P, Yusuf S, Lee SF, Ibrahim Q, Teo K, Rangarajan S, Gupta R, Rosengren A, Lear SA, Avezum A, Lopez-Jaramillo P, Gulec S, Yusufali A, Chifamba J, Lanas F, ... ... Diaz R, et al. Prognostic validation of a non-laboratory and a laboratory based cardiovascular disease risk score in multiple regions of the world. Heart (British Cardiac Society). PMID 29066611 DOI: 10.1136/Heartjnl-2017-311609 |
0.33 |
|
| 2017 |
Wolsk E, Claggett B, Diaz R, Dickstein K, Gerstein HC, Køber L, Lawson FC, Lewis EF, Maggioni AP, McMurray JJV, Probstfield JL, Riddle MC, Solomon SD, Tardif JC, Pfeffer MA. Increases in Natriuretic Peptides Precede Heart Failure Hospitalization in Patients With a Recent Coronary Event and Type 2 Diabetes Mellitus. Circulation. 136: 1560-1562. PMID 29038210 DOI: 10.1161/Circulationaha.117.029503 |
0.386 |
|
| 2017 |
Dehghan M, Mente A, Zhang X, Swaminathan S, Li W, Mohan V, Iqbal R, Kumar R, Wentzel-Viljoen E, Rosengren A, Amma LI, Avezum A, Chifamba J, Diaz R, Khatib R, et al. Associations of fats and carbohydrate intake with cardiovascular disease and mortality in 18 countries from five continents (PURE): a prospective cohort study. Lancet (London, England). PMID 28864332 DOI: 10.1016/S0140-6736(17)32252-3 |
0.324 |
|
| 2017 |
Miller V, Mente A, Dehghan M, Rangarajan S, Zhang X, Swaminathan S, Dagenais G, Gupta R, Mohan V, Lear S, Bangdiwala SI, Schutte AE, Wentzel-Viljoen E, Avezum A, Altuntas Y, ... ... Diaz R, et al. Fruit, vegetable, and legume intake, and cardiovascular disease and deaths in 18 countries (PURE): a prospective cohort study. Lancet (London, England). PMID 28864331 DOI: 10.1016/S0140-6736(17)32253-5 |
0.324 |
|
| 2017 |
Mente A, Dehghan M, Rangarajan S, McQueen M, Dagenais G, Wielgosz A, Lear S, Li W, Chen H, Yi S, Wang Y, Diaz R, Avezum A, Lopez-Jaramillo P, Seron P, et al. Association of dietary nutrients with blood lipids and blood pressure in 18 countries: a cross-sectional analysis from the PURE study. The Lancet. Diabetes & Endocrinology. PMID 28864143 DOI: 10.1016/S2213-8587(17)30283-8 |
0.319 |
|
| 2017 |
Eikelboom JW, Connolly SJ, Bosch J, Dagenais GR, Hart RG, Shestakovska O, Diaz R, Alings M, Lonn EM, Anand SS, Widimsky P, Hori M, Avezum A, Piegas LS, Branch KRH, et al. Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease. The New England Journal of Medicine. PMID 28844192 DOI: 10.1056/Nejmoa1709118 |
0.352 |
|
| 2017 |
Bosch J, Eikelboom JW, Connolly SJ, Bruns NC, Lanius V, Yuan F, Misselwitz F, Chen E, Diaz R, Alings M, Lonn EM, Widimsky P, Hori M, Avezum A, Piegas LS, et al. Rationale, Design and Baseline Characteristics of Participants in the Cardiovascular Outcomes for People Using Anticoagulation Strategies (COMPASS) Trial. The Canadian Journal of Cardiology. 33: 1027-1035. PMID 28754388 DOI: 10.1016/J.Cjca.2017.06.001 |
0.356 |
|
| 2017 |
Gerstein HC, Colhoun HM, Dagenais GR, Diaz R, Lakshmanan M, Pais P, Probstfield J, Riddle MC, Rydén L, Xavier D, Atisso CM, Avezum A, Basile J, Chung N, Conget I, et al. Design and Baseline Characteristics of Participants in the Researching cardiovascular Events with a Weekly INcretin in Diabetes (REWIND) Trial of Dulaglutide's Cardiovascular Effects. Diabetes, Obesity & Metabolism. PMID 28573765 DOI: 10.1111/Dom.13028 |
0.321 |
|
| 2017 |
Wolsk E, Claggett B, Pfeffer MA, Diaz R, Dickstein K, Gerstein HC, Lawson FC, Lewis EF, Maggioni AP, McMurray JJV, Probstfield JL, Riddle MC, Solomon SD, Tardif JC, Køber L. Role of B-Type Natriuretic Peptide and N-Terminal Prohormone BNP as Predictors of Cardiovascular Morbidity and Mortality in Patients With a Recent Coronary Event and Type 2 Diabetes Mellitus. Journal of the American Heart Association. 6. PMID 28554908 DOI: 10.1161/Jaha.116.004743 |
0.346 |
|
| 2017 |
Goodman SG, Schwartz G, Bhatt DL, Bittner V, Diaz R, Hanotin C, Harrington R, Jukema J, Moryusef A, Pordy R, Roe M, Sasiela WJ, Szarek M, Tamby J, White H, et al. Use Of High-Intensity Statin Therapy Post-Acute Coronary Syndrome In The Ongoing Odyssey Outcomes Trial Of Alirocumab, A Proprotein Convertase Subtilisin/Kexin Type 9 Monoclonal Antibody, Versus Placebo: Interim Baseline Data Journal of the American College of Cardiology. 69: 153. DOI: 10.1016/S0735-1097(17)33542-8 |
0.376 |
|
| 2017 |
White H, Goodman S, Schwartz G, Bhatt D, Bittner V, Diaz R, Hanotin C, Harrington R, Jukema J, Moryusef A, Pordy R, Roe M, Sasiela W, Szarek M, Tamby J, et al. Use of High-Intensity Statin Therapy Post-Acute Coronary Syndrome in the Ongoing ODYSSEY OUTCOMES Trial of Alirocumab, A Proprotein Convertase Subtilisin/Kexin type 9 Monoclonal Antibody, Versus Placebo: Interim Baseline Data Heart Lung and Circulation. 26. DOI: 10.1016/J.Hlc.2017.06.604 |
0.334 |
|
| 2016 |
Mente A, O'Donnell M, Rangarajan S, Dagenais G, Lear S, McQueen M, Diaz R, Avezum A, Lopez-Jaramillo P, Lanas F, Li W, Lu Y, Yi S, Rensheng L, Iqbal R, et al. Associations of urinary sodium excretion with cardiovascular events in individuals with and without hypertension: a pooled analysis of data from four studies. Lancet (London, England). PMID 27216139 DOI: 10.1016/S0140-6736(16)30467-6 |
0.335 |
|
| 2016 |
Lonn EM, Bosch J, López-Jaramillo P, Zhu J, Liu L, Pais P, Diaz R, Xavier D, Sliwa K, Dans A, Avezum A, Piegas LS, Keltai K, Keltai M, Chazova I, et al. Blood-Pressure Lowering in Intermediate-Risk Persons without Cardiovascular Disease. The New England Journal of Medicine. PMID 27041480 DOI: 10.1056/Nejmoa1600175 |
0.303 |
|
| 2016 |
Yusuf S, Bosch J, Dagenais G, Zhu J, Xavier D, Liu L, Pais P, López-Jaramillo P, Leiter LA, Dans A, Avezum A, Piegas LS, Parkhomenko A, Keltai K, Keltai M, ... ... Diaz R, et al. Cholesterol Lowering in Intermediate-Risk Persons without Cardiovascular Disease. The New England Journal of Medicine. PMID 27040132 DOI: 10.1016/J.Jvs.2016.07.054 |
0.362 |
|
| 2016 |
Yusuf S, Lonn E, Pais P, Bosch J, López-Jaramillo P, Zhu J, Xavier D, Avezum A, Leiter LA, Piegas LS, Parkhomenko A, Keltai M, Keltai K, Sliwa K, Chazova I, ... ... Diaz R, et al. Blood-Pressure and Cholesterol Lowering in Persons without Cardiovascular Disease. The New England Journal of Medicine. PMID 27039945 DOI: 10.1056/Nejmoa1600177 |
0.335 |
|
| 2015 |
Pfeffer MA, Claggett B, Diaz R, Dickstein K, Gerstein HC, Køber LV, Lawson FC, Ping L, Wei X, Lewis EF, Maggioni AP, McMurray JJ, Probstfield JL, Riddle MC, Solomon SD, et al. Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome. The New England Journal of Medicine. 373: 2247-2257. PMID 26630143 DOI: 10.1056/Nejmoa1509225 |
0.369 |
|
| 2015 |
Ng KH, Shestakovska O, Connolly SJ, Eikelboom JW, Avezum A, Diaz R, Lanas F, Yusuf S, Hart RG. Efficacy and safety of apixaban compared with aspirin in the elderly: a subgroup analysis from the AVERROES trial. Age and Ageing. PMID 26590293 DOI: 10.1093/Ageing/Afv156 |
0.311 |
|
| 2015 |
Khatib R, McKee M, Shannon H, Chow C, Rangarajan S, Teo K, Wei L, Mony P, Mohan V, Gupta R, Kumar R, Vijayakumar K, Lear SA, Diaz R, Avezum A, et al. Availability and affordability of cardiovascular disease medicines and their effect on use in high-income, middle-income, and low-income countries: an analysis of the PURE study data. Lancet (London, England). PMID 26498706 DOI: 10.1016/S0140-6736(15)00469-9 |
0.31 |
|
| 2015 |
Bonaca MP, Bhatt DL, Steg PG, Storey RF, Cohen M, Im K, Oude Ophuis T, Budaj A, Goto S, López-Sendón J, Diaz R, Dalby A, Van de Werf F, Ardissino D, Montalescot G, et al. Ischaemic risk and efficacy of ticagrelor in relation to time from P2Y12 inhibitor withdrawal in patients with prior myocardial infarction: insights from PEGASUS-TIMI 54. European Heart Journal. PMID 26491109 DOI: 10.1093/Eurheartj/Ehv531 |
0.334 |
|
| 2015 |
Lonn E, Bosch J, Pogue J, Avezum A, Chazova I, Dans A, Diaz R, Fodor GJ, Held C, Jansky P, Keltai M, Keltai K, Kunti K, Kim JH, Leiter L, et al. Novel Approaches in Primary Cardiovascular Disease Prevention: The HOPE-3 Trial Rationale, Design, and Participants' Baseline Characteristics. The Canadian Journal of Cardiology. PMID 26481083 DOI: 10.1016/J.Cjca.2015.07.001 |
0.367 |
|
| 2015 |
Khan R, Lopes RD, Neely ML, Stevens SR, Harrington RA, Diaz R, Cools F, Jansky P, Montalescot G, Atar D, Lopez-Sendon J, Flather M, Liaw D, Wallentin L, Alexander JH, et al. Characterising and predicting bleeding in high-risk patients with an acute coronary syndrome. Heart (British Cardiac Society). PMID 26109589 DOI: 10.1136/Heartjnl-2014-307346 |
0.394 |
|
| 2015 |
Bentley-Lewis R, Aguilar D, Riddle MC, Claggett B, Diaz R, Dickstein K, Gerstein HC, Johnston P, Køber LV, Lawson F, Lewis EF, Maggioni AP, McMurray JJ, Ping L, Probstfield JL, et al. Rationale, design, and baseline characteristics in Evaluation of LIXisenatide in Acute Coronary Syndrome, a long-term cardiovascular end point trial of lixisenatide versus placebo. American Heart Journal. 169: 631-638.e7. PMID 25965710 DOI: 10.1016/J.Ahj.2015.02.002 |
0.398 |
|
| 2015 |
Orlandini A, Castellana N, Pascual A, Botto F, Cecilia Bahit M, Chacon C, Luz Diaz M, Diaz R. Myocardial viability for decision-making concerning revascularization in patients with left ventricular dysfunction and coronary artery disease: a meta-analysis of non-randomized and randomized studies. International Journal of Cardiology. 182: 494-9. PMID 25617608 DOI: 10.1016/J.Ijcard.2015.01.025 |
0.341 |
|
| 2015 |
Pfeffer MA, Claggett B, Assmann SF, Boineau R, Anand IS, Clausell N, Desai AS, Diaz R, Fleg JL, Gordeev I, Heitner JF, Lewis EF, O'Meara E, Rouleau JL, Probstfield JL, et al. Regional variation in patients and outcomes in the Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT) trial. Circulation. 131: 34-42. PMID 25406305 DOI: 10.1161/Circulationaha.114.013255 |
0.308 |
|
| 2015 |
Bonaca MP, Bhatt DL, Steg PG, Budaj A, Bansilal S, Storey RF, Im K, Magnani G, Ophuis TO, Ruda M, Hamm C, Spinar J, Kiss RG, Diaz R, Van de Werf FJ, et al. TCT-78 Efficacy of Long-Term Ticagrelor in Stented Patients in PEGASUS-TIMI 54 Journal of the American College of Cardiology. 66: B36. DOI: 10.1016/J.Jacc.2015.08.121 |
0.301 |
|
| 2014 |
Yusuf S, Rangarajan S, Teo K, Islam S, Li W, Liu L, Bo J, Lou Q, Lu F, Liu T, Yu L, Zhang S, Mony P, Swaminathan S, Mohan V, ... ... Diaz R, et al. Cardiovascular risk and events in 17 low-, middle-, and high-income countries. The New England Journal of Medicine. 371: 818-27. PMID 25162888 DOI: 10.1056/Nejmoa1311890 |
0.343 |
|
| 2014 |
O'Donnell M, Mente A, Rangarajan S, McQueen MJ, Wang X, Liu L, Yan H, Lee SF, Mony P, Devanath A, Rosengren A, Lopez-Jaramillo P, Diaz R, Avezum A, Lanas F, et al. Urinary sodium and potassium excretion, mortality, and cardiovascular events. The New England Journal of Medicine. 371: 612-23. PMID 25119607 DOI: 10.1056/Nejmoa1311889 |
0.302 |
|
| 2014 |
White HD, Held C, Stewart R, Tarka E, Brown R, Davies RY, Budaj A, Harrington RA, Steg PG, Ardissino D, Armstrong PW, Avezum A, Aylward PE, Bryce A, ... ... Diaz R, et al. Darapladib for preventing ischemic events in stable coronary heart disease. The New England Journal of Medicine. 370: 1702-11. PMID 24678955 DOI: 10.1056/Nejmoa1315878 |
0.337 |
|
| 2013 |
Teo K, Lear S, Islam S, Mony P, Dehghan M, Li W, Rosengren A, Lopez-Jaramillo P, Diaz R, Oliveira G, Miskan M, Rangarajan S, Iqbal R, Ilow R, Puone T, et al. Prevalence of a healthy lifestyle among individuals with cardiovascular disease in high-, middle- and low-income countries: The Prospective Urban Rural Epidemiology (PURE) study. Jama. 309: 1613-21. PMID 23592106 DOI: 10.1001/Jama.2013.3519 |
0.306 |
|
| 2011 |
Alexander JH, Lopes RD, James S, Kilaru R, He Y, Mohan P, Bhatt DL, Goodman S, Verheugt FW, Flather M, Huber K, Liaw D, Husted SE, Lopez-Sendon J, De Caterina R, ... ... Diaz R, et al. Apixaban with antiplatelet therapy after acute coronary syndrome. The New England Journal of Medicine. 365: 699-708. PMID 21780946 DOI: 10.1056/Nejmoa1105819 |
0.326 |
|
| 2003 |
Simes J, White HD, Marschner IC, Varshavsky S, Diaz R, French JK, Aylward P. International differences in patients, care and outcomes associated with acute myocardial infarction (AMI): the HERO-2 trial Heart Lung and Circulation. 12. DOI: 10.1046/J.1443-9506.2003.0120X.X |
0.332 |
|
| 2001 |
Sleight P, Yusuf S, Pogue J, Tsuyuki R, Diaz R, Probstfield J. Blood-pressure reduction and cardiovascular risk in HOPE study The Lancet. 358: 2130-2131. PMID 11784631 DOI: 10.1016/S0140-6736(01)07186-0 |
0.344 |
|
| 2001 |
Mehta SR, Eikelboom JW, Natarajan MK, Diaz R, Yi C, Gibbons RJ, Yusuf S. Impact of right ventricular involvement on mortality and morbidity in patients with inferior myocardial infarction. Journal of the American College of Cardiology. 37: 37-43. PMID 11153770 DOI: 10.1016/S0735-1097(00)01089-5 |
0.324 |
|
| 1997 |
Díaz R, Yusuf S. Selection of patients for angiography following myocardial infarction was not based on risk but on young age and availability of angiographic facilities. Evidence-Based Cardiovascular Medicine. 1: 52. PMID 16379717 DOI: 10.1016/S1361-2611(97)80044-9 |
0.312 |
|
| 1994 |
Barbash GI, White HD, Modan M, Diaz R, Hampton JR, Heikkila J, Kristinsson A, Moulopoulos S, Paolasso EA, Van der Werf T. Outcome of thrombolytic therapy in relation to hospital size and invasive cardiac services. The Investigators of the International Tissue Plasminogen Activator/Streptokinase Mortality Trial. Archives of Internal Medicine. 154: 2237-42. PMID 7944845 DOI: 10.1001/Archinte.1994.00420190141016 |
0.332 |
|
| Show low-probability matches. |